| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
Purity: ≥98%
| Targets |
Fungal[1].
AN2718 targets leucyl-transfer RNA synthetase (LeuRS), an essential enzyme in protein synthesis. It acts by blocking protein synthesis through the OBORT (oxaborole tRNA capture) mechanism. By inhibiting LeuRS, AN2718 prevents the charging of tRNA with leucine, thereby halting protein synthesis in fungal cells. This leads to inhibition of fungal growth. Its mechanism is specific to fungi, making it a promising antifungal agent. |
|---|---|
| ln Vitro |
Molds (A. fumigatus) and yeasts (C. albicans) have cytoplasmic LeuRS inhibition by AN2718, with IC50 values of 2 μM and 4.2 μM, respectively. T. rubrum and T. mentagrophytes are two dermatophytes that AN2718 exhibits strong MIC90 activity against[1].
In vitro, AN2718 demonstrates potent antifungal activity against a range of dermatophytes and other fungi. It has good MIC90 activity against the dermatophytes T. rubrum and T. mentagrophytes. Its activity is assessed using standard broth microdilution assays to determine the minimum inhibitory concentration (MIC). Its mechanism of action involves the inhibition of leucyl-tRNA synthetase, as demonstrated in enzymatic assays. |
| ln Vivo |
In vivo, AN2718 is used topically for the treatment of onychomycosis. Its efficacy in treating fungal nail infections has been demonstrated in preclinical and clinical studies. As a topical agent, it is applied directly to the affected nails, minimizing systemic exposure. Its boron-containing structure is key to its antifungal activity and its ability to penetrate the nail plate.
|
| Enzyme Assay |
The in vitro enzyme assay for AN2718 measures its ability to inhibit leucyl-transfer RNA synthetase (LeuRS) activity. These cell-free assays use purified LeuRS and measure the charging of tRNA with leucine in the presence of the compound. The inhibitory potency (IC50) is determined by measuring the reduction in enzyme activity. These assays confirm its mechanism of action as a LeuRS inhibitor.
|
| Cell Assay |
In vitro cellular assays for AN2718 assess its antifungal activity against fungal pathogens. Fungi such as T. rubrum or T. mentagrophytes are cultured in the presence of various concentrations of AN2718. Fungal growth is measured, and the minimum inhibitory concentration (MIC) is determined. These assays demonstrate the compound's functional activity against clinically relevant fungal species.
|
| Animal Protocol |
In vivo animal studies for AN2718 have been conducted in models of dermatophyte infections to evaluate its efficacy. These studies typically involve infecting animals with fungi and then treating them topically with AN2718. The reduction in fungal burden and clinical improvement are assessed. However, specific details of these studies are not extensively detailed in the available literature.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for AN2718 are not extensively detailed in the available literature. As a topical agent, its systemic absorption is expected to be minimal. Its stability in solution is rarely reported. Its pharmacokinetic properties would be important for its development as a therapeutic agent, but specific data are not provided in the search results.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for AN2718 are not extensively detailed in the available literature. As a topical antifungal, its toxicity is expected to be low due to minimal systemic absorption. However, comprehensive toxicological studies would be required to establish its safety profile for therapeutic use. It is intended for research purposes only.
|
| References |
|
| Additional Infomation |
An2718 has been used in trials for research on athlete's foot.
AN2718 is a novel boron-containing benzoxaborole antifungal that inhibits leucyl-tRNA synthetase via the OBORT mechanism. It has good activity against dermatophytes like T. rubrum and T. mentagrophytes. It is being developed for the topical treatment of onychomycosis. It is not approved for clinical use and is intended for research purposes. |
| Molecular Formula |
C7H6BCLO2
|
|---|---|
| Molecular Weight |
168.383
|
| Exact Mass |
168.015
|
| Elemental Analysis |
C, 49.93; H, 3.59; B, 6.42; Cl, 21.05; O, 19.00
|
| CAS # |
174672-06-1
|
| Related CAS # |
174672-06-1
|
| PubChem CID |
11845944
|
| Appearance |
White to off-white solid powder
|
| LogP |
0.557
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
11
|
| Complexity |
155
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OB1OCC2=CC(Cl)=CC=C21
|
| InChi Key |
HMAFTPZYFJFEHK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H6BClO2/c9-6-1-2-7-5(3-6)4-11-8(7)10/h1-3,10H,4H2
|
| Chemical Name |
5-chlorobenzo[c][1,2]oxaborol-1(3H)-ol
|
| Synonyms |
AN2718; AN-2718; AN 2718
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 34~250 mg/mL ( 201.91~1484.65 mM )
Ethanol : ~34 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (12.35 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (12.35 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (12.35 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.9389 mL | 29.6947 mL | 59.3895 mL | |
| 5 mM | 1.1878 mL | 5.9389 mL | 11.8779 mL | |
| 10 mM | 0.5939 mL | 2.9695 mL | 5.9389 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00781664 | Completed | Other: AN2718 Drug: AN2718 Drug: AN2718 |
Tinea Pedis | Pfizer | 2008-10 | Phase 1 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA